To date, no certain cure has been found for patients with degenerative
cerebellar disease. In this trial, we examined the in vivo and in vitro
neuroprotective effects of Sertoli cells (SCs) on alleviating the symptoms of
cerebellar ataxia. Testicular cells from an immature male rat were isolated and characterized by immunocytochemical analysis for somatic cell markers (
anti-Mullerian hormone,
vimentin). The
protein assessment had already confirmed the expression of
neurotrophic factors of
glial cell line-derived neurotrophic factor (
GDNF) and vascular endothelial factor (
VEGF). In vitro neuroprotective impact of SCs was determined after exposing PC12 cells to Sertoli cell-
conditioned media (SC-CM) and H2O2, simultaneously. Afterwards,
ataxia rat models were induced by a single dose of 3-AP (3-acetylpyridin), and 3 days later, SCs were bilaterally implanted. Motor and neuromuscular activity test were conducted following SC
transplantation. Finally, immunohistochemistry against RIPK3 and Iba-1 was done in our generation. The in vivo results revealed substantial improvement in neuromuscular response, while
ataxia group exhibited aggravated condition over a 28-day period. Our results suggested enhanced motor function and behavioral characteristics due to the ability of SCs to suppress necroptosis and consequently extend cell survival. Nevertheless, more studies are required to affirm the therapeutic impacts of SC
transplantation in human
cerebellar ataxia. In vitro data indicated cell viability was increased as a result of SC-CM with a significant reduction in ROS.